top of page


Dapagliflozin is approved for treating paediatric type 2 diabetes
Type 2 diabetes mellitus (T2D) is a progressive metabolic disease that affects members of all ages but is more common in people over 45 years (1). Type 2 diabetes has recently become more common among children, adolescents, and young adults around the world. In 2021, about 41,600 new cases of youth-onset diabetes were reported worldwide (2). The prevalence of youth-onset T2D among children aged 10–19 is 0.67 per 1000, a 95.3% increase since 2001. Additionally, 1 in 5 adolesce

Dr. Geetika Gupta
Sep 10, 20256 min read
bottom of page